New protease inhibitors showing promise for HIV/HCV coinfection
Although use of telaprevir or boceprevir in the HIV/HCV coinfected
patient would be considered off-label, consideration should be given to
utilizing these agents when HCV treatment is desired because the current
evidence shows a substantial improvement in treatment success.
This is an exciting time in the treatment of chronic hepatitis C
virus infections. As opposed to the antibiotic pipeline, there are a
number of new antiviral agents for treatment of hepatitis C in
development that may transform the way these patients are treated.
Chronic infection with HCV has emerged as a major cause of morbidity
and mortality in those living with HIV infection. Approximately 15% to
30% of patients with HIV in the United States are estimated to be
coinfected with HIV and HCV. All patients with HIV/HCV coinfection
should be evaluated for HCV therapy because of the more rapid
progression of liver disease in those with HCV alone, and because the
successful treatment of HCV may also reduce the risk for hepatotoxicity
from the use of HAART in these patients.